PubMed HealthSearch

Biomedical subjects

P Mikaeloff

Publications and source records attributed to P Mikaeloff.

At least 19 recordsLinked to original sources

Glucose and insulin supply before cardiopulmonary bypass in cardiac surgery: a double-blind study.

A double-blind study versus placebo was carried out to evaluate the effects of a 500-mL infusion of 30% glucose containing 300 units of ordinary insulin and 5 g of potassium chloride administered at a rate of 1.66 mL.kg-1.h-1 for 1 hour before cardiopulmonary bypass. The hemodynamic parameters measured before and after administration of the solution, after cardiopulmonary bypass, after administration of protamine, and 3 hours after leaving the operating room showed the beneficial effect of the glucose-insulin-potassium infusion on cardiac index (+23.6% after protamine infusion) and left (+16.3% 3 hours postoperatively) and right (+47.3% after cardiopulmonary bypass) ventricular workload index with a decrease in systemic vascular resistance. For patients with a cardiac index of less than 2.5 L.min-1.m-2 before administration of the glucose-insulin-potassium solution, the beneficial effect on the cardiac index was further increased 3 hours postoperatively (+33%). During the postoperative period, the requirements in inotropic drugs and disturbances of rhythm were not significantly different between the two groups, although they were twofold lower in patients receiving glucose-insulin-potassium. Laboratory tests showed that postoperative hypoglycemia was more common in the glucose-insulin-potassium group but had no detrimental effects; it no longer occurs since we began administering the glucose infusion at 15 g/h over 8 hours. The data reflect the beneficial effect associated with the action of glucose-insulin-potassium on myocardial protection during heart operations and were confirmed by the hemodynamic results. This argues in favor of the routine use of this technique, especially in patients with poor ventricular function.

Cardiac Surgical Procedures

Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion.

Ninety patients undergoing cardiac surgery were randomly divided into three groups of 30 patients to compare the effects on bleeding and transfusion requirements of either intraoperative infusion of high-dose aprotinin (GpI) or reinfusion of autologous fresh whole blood (GpII) versus a control group (GpIII). Standardized anesthetic, perfusion, and surgical techniques were used. Platelet counts, hemoglobin concentration, hematocrit, fibrinogen, and Ivy-Nelson bleeding times determined at fixed times perioperatively did not differ among the three groups. The total loss from the chest drains was significantly reduced in GpI (328 +/- 28 mL; mean +/- SEM) as compared with the loss in GpII and GpIII (775 +/- 75 mL and 834 +/- 68 mL, respectively). There was a threefold difference in the total hemoglobin loss (GpI, 14.2 +/- 1.7 g; GpII, 50.1 +/- 5.0 g; GpIII, 45.0 +/- 5.2 g). GpI patients also received less banked blood: 250 +/- 53 mL versus 507 +/- 95 mL in GpII and 557 +/- 75 mL in GpIII. No GpI patient required transfusion of platelets or fresh frozen plasma. Fresh whole autologous blood transfusions had no significant hemostatic effect and failed to reduce the homologous blood requirement. Conversely, high-dose aprotinin reduced blood loss and transfusion requirements.

Adult

[Clinical and hemodynamic prognosis after tricuspid valve replacement with bioprosthesis].

Between 1974 and 1990, 58 patients underwent tricuspid valve replacement with a porcine bioprosthesis (Hancock 42, Carpentier-Edwards 16) in the course of polyvalvular replacement (double 21, triple 37). Early postoperative mortality was 12%: 16 patients died secondarily, usually of cardiac causes. The actuarial survival (1 patient lost to follow-up) was 81 +/- 11% at 5 years and 60 +/- 17% at 10 years. Two patients were reoperated for dysfunction of a Hancock bioprosthesis, 11 and 15 years after implantation. At long-term, with an average follow-up of 108 +/- 48 months, 82% of survivors (28/34) were clinically improved. Doppler echocardiography was performed in 29 patients in February 1991. In 21 cases, with a follow-up of 88 +/- 40 months, the bioprosthesis was normal with an average diastolic transprosthetic pressure gradient of 3.8 +/- 1.7 mmHg. In 7 patients followed up for 129 +/- 40 months (p < 0.05) moderate dysfunction of the Hancock prosthesis was observed with a mean diastolic pressure. Severe dysfunction of a Hancock prosthesis was observed in 1 case. Fixed pulmonary hypertension was noted in 11 cases and was associated with a poor clinical result and a raised mean diastolic transprosthetic pressure gradient. The durability and haemodynamic performance of tricuspid porcine bioprostheses are satisfactory in the long term. Prosthetic dysfunction is correlated to the duration of implantation of the bioprosthesis and to persistent pulmonary hypertension.

Actuarial Analysis

[Long-term surgical prognosis of aortic valve diseases with pulmonary hypertension. Apropos of 34 cases].

Thirty-four patients underwent isolated aortic valve replacement with mean pulmonary artery pressures greater than 40 mmHg between 1972 and 1988. The aortic valve disease was stenotic in 10 cases, regurgitant in 14 cases and mixed in 10 cases. Thirty patients (88%) had invalidating cardiac failure (NYHA Classes III and IV). The mean preoperative ejection fraction was 44 +/- 15%. The hospital mortality was 17.6%. Ten patients died secondarily, five with terminal cardiac failure. The 5 year actuarial survival was 70 +/- 16%; the 10 year survival was 60 +/- 18% with an average follow-up of 115 +/- 61 months. None of the patients was lost to follow-up. Fifteen of the 18 survivors (83%) are asymptomatic or pauci-symptomatic after a follow-up of 126 +/- 62 months. Doppler echocardiography (n = 12) showed normal prosthetic valve function in 11 cases and aortic regurgitation in 1 case. Eight patients had tricuspid regurgitation with pulmonary artery systolic pressures less than 30 mmHg in 6 cases and between 30 and 40 mmHg in 2 cases. Severe pulmonary hypertension is therefore a poor early postoperative prognostic factor in aortic valve replacement surgery due to the associated left ventricular dysfunction. However, the long-term results are satisfactory: clinical improvement is usually related to a reduction of pulmonary hypertension.

Actuarial Analysis

[Heart surgery in the elderly].

Between january 1987 and january 1990, 115 patients aged over 70 (mean: 75 +/- 3 years) underwent heart surgery performed by our team. Fifty-three had coronary artery bypass graft surgery alone, 44 had cardiac valve surgery alone and 18 had combined coronary and cardiac valve surgery; 88 percent of the patients were in NYHA functional class III or IV, and 79 percent presented with left ventricular dysfunction. The early postoperative mortality rate was 7 percent: 5.6 percent in coronary bypass surgery alone, 8 percent in cardiac valve surgery alone and 22 percent in combined coronary and valve surgery. After a mean follow-up period of 22 +/- 8 months, 85 percent of the patients are asymptomatic or exhibit few symptoms. The actuarial survival rate at 3 years is 78 +/- 10 percent. Thus, in 1990 age is lo longer an obstacle to heart surgery. In most cases the operative risk is controlled by a surgical strategy where the physiopathology of the elderly is taken into account and the appropriate surgical techniques are applied.

Aged

[Mitral valve replacement in severe pulmonary hypertension. Long-term results].

Between 1972 and 1987, 43 patients underwent isolated mitral valve replacement with mean pulmonary arterial pressures greater than 50 mmHg. The valve disease was stenosis in 13 cases, regurgitation in 15 cases and mixed mitral valve disease in 15 cases. Forty-one patients (95 %) had invalidating cardiac failure (Stages III and IV of the NYHA Classification). The hospital mortality was 2.3%. Thirteen patients died during follow-up, 8 of cardiac failure, 3 of sudden death and 2 died of non-cardiac causes. The 8 year actuarial survival was 82 +/- 7% with an average postoperative follow-up of 96 +/- 41 months. No patients were lost to follow-up. Eighty six per cent of survivors (25/29) are asymptomatic or paucisymptomatic. Doppler studies were performed in 22 patients, showing normal prosthetic function in 18 cases and an obstructive prosthesis in 4 cases. Seventeen patients had tricuspid regurgitation showing normal pulmonary artery systolic pressures in 9 cases and less than 55 mmHg in 5 cases. On average, systolic pulmonary artery pressure fell from 88 +/- 11 mmHg before to 33 +/- 9 mmHg after surgery (p = 0.01). These results show that severe pulmonary hypertension is not prohibitive for mitral valve replacement. The long-term results are good with functional improvement and reduction of pulmonary hypertension.

Actuarial Analysis

[Late results of isolated aortic valve replacement by Björk-Shiley prosthesis. Apropos of 596 cases].

Between 1970 and 1985, 596 patients underwent isolated aortic valve replacement with a Björk-Shiley prosthesis: 448 men and 148 women, average age 52 +/- 13 years (range 10-78 years). The valve lesion was aortic stenosis in 158 cases, aortic regurgitation in 218 cases and mixed valve disease in 220 cases. Fifty-four per cent of patients had invalidating cardiac failure (Stage III of the NYHA Classification). Thirteen per cent of patients had an associated non valvular surgical procedure. The hospital mortality was 5.7% and 77% of the early deaths were of cardiac origin. Results were analysed after an average follow-up period of 90 +/- 15 months, a total of 3817 patient-years. The late mortality was 94 (16.7%). Actuarial survival was 87 +/- 1% at 5 years and 79 +/- 2% at 10 years. A prognostic score was established from a multifactorial analysis: Cox = 0.44 (NYHA Stage 1, 2, 3, 4) + 5.29 C/T (absolute value) + 1.15 associated procedure (0.1) + 0.65 (RBBB) (0.1). In the long-term, 84.8% of survivors were asymptomatic (NYHA Stages I and II). The incidence of thrombo-embolism was 0.5/100 patient-years. At 10 years, 95% of patients had no thromboembolic complication. The incidence of ineffective endocarditis was 0.3/100 patient-years and that of complications of anticoagulant therapy was 0.4/100 patient-years. The incidence of valve dehiscence was 0.1/100 patient-years and the reoperation rate was 0.4/100 patient-years but there were no cases of valve dysfunction. The global complication rate in this series was 1.35/100 patient-years. These results confirm the good results of aortic valve replacement with a mechanical prosthesis.(ABSTRACT TRUNCATED AT 250 WORDS)

Actuarial Analysis

[Long-term results and prognostic factors after mitral valve replacement using the Starr-Edwards 6120 prosthesis].

Between 1970 and 1984, 386 mitral valve replacements with the SE 6120 prosthesis were performed with a mean post-operative follow-up of 75 +/- 44 months or a total follow-up of 2520 patient years (PY). Rapid post-operative mortality was 6.7 percent and the delayed mortality 26.5 percent, the 5-year actuarial survival rate was 80 +/- 2% and that at 10 years 67 +/- 2% (including early mortality). There was no significant difference for survival between single-valve replacements (n = 183) and multiple-valve replacements (n = 203). Multifactorial prognosis analysis (Cox) gave two post-operative prognosis: X (n = 386) = 0.0391 (age) + 0.2421 (NYHA stage); Y (n = 147) = 0.8561 (X) + 0.6299 (VG type). The incidence of complications related to the prosthesis is 4.16 per 100 PY, including sudden deaths. The current actuarial analysis shows that at 5 years 91 +/- 1% at 10 years 78 +/- 2% of the operated subjects are devoid of any such complication and of thrombosis of the valve. Statistically, it was found that permanent atrial fibrillation (p = 0.03), the size of the right atrium (p = 0.02) played a promoting role. With a post-operative follow-up in excess of 8 years. 79% of the survivors are symptom-free or present few symptoms and the myocardial response is poor in 52 patients (NYHA stage III or IV).

Adult

[Echocardiography in selecting patients to undergo Carpentier's mitral valvuloplasty].

The aim of this study was to confront preoperative echocardiographic data with the anatomic operative findings in patients with mitral insufficiency (MI) undergoing Carpentier's mitral valvuloplasty in order to determine the mechanism(s) of the regurgitation, to classify MI by the echocardiographic changes and to thereby answer the question as to whether echocardiography can identify the patients likely to benefit from this operation. Between February 1985 and November 1987, 66 patients (47 men, 19 women, average age 58 +/- 9 years) with pure MI were referred for surgery with a view to mitral valvuloplasty. This operation was possible in 49 patients (2 of 6 rheumatic MI and 47 of 60 dystrophic MI). The sensitivity of echocardiography was excellent and its specificity very good in diagnosing prolapse of one or the other mitral leaflets. Echocardiography was not as good in distinguishing rupture from elongation of the chordae tendinae and myxoid degeneration from fibro-elastic leaflets. Echocardiography allowed preoperative classification of MI in 4 groups: Group 1 (n = 46) with prolapse of the posterior leaflet; Group 2 (n = 4) with prolapse of the anterior leaflet; Group 3 (n = 8) with prolapse of both mitral leaflets; Group 4 (n = 2) with abnormalities of the mitral annulus alone. Carpentier's valvuloplasty was possible in 43/46 patients in Group 1, 2/4 patients in Group 2, 1/8 patients in Group 3 and 1/2 patients in Group 4. In conclusion, echocardiography is a good tool for selecting patients with dystrophic MI for Carpentier's valvuloplasty.

Aged

[Cardiac surgery in the elderly].

In 1990, by consensus, the elderly patient in terms of cardiac surgery is a patient aged over 70. The special features of this population include the severity of symptomatology, the high incidence of left ventricular dysfunction and the high incidence of concomitant pathology. In the majority of cases the operative risk is controlled by a surgical strategy which takes into account the pathophysiology of the elderly patient and surgical techniques appropriate in the elderly. Over a 3 year period (1987-1990), 115 patients aged over 70 underwent cardiac surgery at the hands of our team with an early postoperative mortality rate of 7%: 5.6% following coronary surgery only, 8% following valve surgery only, 22% following combined surgery. Improved life expectancy and quality of life of patients was the rule in the majority of cases, thus fulfilling the aims of surgery.

Aged

[Doppler echography in the evaluation of mitral valve function following Carpentier's valvuloplasty].

In the present study Doppler-echocardiography was used to evaluate the quality of mitral valve regurgitation (MVR) repair by Carpentier valvuloplasty. Between January, 1984 and June, 1987, this operation was performed in 51 patients (39 men, 12 women; mean age 58 +/- 10.9 years) presenting with mitral valve regurgitation; 25 were in class III and 14 in class IV of the NYHA classification. Two patients died soon after the operation and 2 others some time later. The 47 survivors were followed up for a mean period of 20.5 +/- 11.2 months: 3 of them required mitral valve replacement for residual MVR or mitral stenosis, one developed cerebral embolism. At the latest control, 18 patients were in NYHA class I and 26 in NYHA class II. Doppler velocimetry showed no or little mitral valve dysfunction; the residual MVR was below grade 1 in 37 of the 44 survivors who were not reoperated upon. Mitral function was satisfactory after Carpentier valvuloplasty, with a mean transmitral gradient of 3.3 +/- 1.3 mmHg and a mean mitral valve area of 2.9 +/- 0.98 cm2. In 3 patients an intraventricular gradient of 10 to 20 mmHg, reflecting moderate ventricular obstruction, was detected by Doppler velocimetry. These data obtained with the combined Doppler-echocardiographic method confirm that the quality of mitral function is excellent after Carpentier mitral valvuloplasty.

Aged

[Prognosis of chronic non-dystrophic and surgically treated aortic insufficiency].

Between January 1972 and March 1983, 123 patients with isolated non dystrophic aortic insufficiency underwent aortic valve replacement. During a mean follow-up period of 4.3 years per patient, 25.6 p. 100 of the patients died, including a 4.1 p. 100 hospital death rate. The actuarial survival rate was 74 p. 100 at 5 years and 62 p. 100 at 10 years. The main causes of mortality were heart failure, dysrhythmias and sudden death. A study of prognostic factors based on the preoperative data showed that clinical, radiological, electrocardiographic and haemodynamic signs were informative. In agreement with other authors, we found that preoperative cardiac dilatation and left ventricular dysfunction were predictive of a poor prognosis.

Adult

[Late results of myocardial revascularization surgery in patients with severe impairment of left ventricle dynamics. Apropos of 80 cases surgically treated from 1970 to 1979].

Coronary bypass surgery was performed on forty-eight patients with LVD from 1970 to 1979. Mean age was 53 +/- 9 years. All patients had abnormal motion of all walls on cineangiography and three vessel disease. Mean LVEF was 27.7%. Mean of distal anastomoses was 1.6 per patient with internal mammary artery graft to LAD. Six patients died early postoperatively (7.5%) and there were 31 late deaths. Actuarial survival including early deaths is 71.5 (+/- 6)% 5 years and 49% 10 years postoperatively. LVEF has a significant influence upon late survival (p 0.01). Because of incomplete revascularization, 55% of the 40 surviving patients, have recurrence of angina with a mean follow-up of 103 months. We have subsequently increased the mean number of bypass grafts in these patients.

Actuarial Analysis

[Clinical and metabolic evaluation of myocardial protection by oxygenated cardioplegia (Hamburg solution) in multiple coronary bypass surgery or polyvalvular replacement].

Myocardial protection by the Hamburg oxygenated crystalloid cardioplegic solution was evaluated. A prospective metabolic study was conducted by measuring the myocardial adenosine triphosphate (ATP) and creatine phosphate (CP) contents by enzymatic techniques in 30 coronary bypass patients with a mean of 3.5 (+/- 0.9) aorto-coronary bypass grafts. Mean aortic cross clamp time was 48.4 (+/- 9.8) min. Myocardial samples were obtained from the left anterolateral ventricular wall: 1 = before CPB, 2 = before aortic cross clamp removal, 3 = 10 min following reperfusion. During ischemia, there was no statistically significant decrease in myocardial ATP contents [3.26 (+/- 0.82) vs 3.01 (+/- 0.92) mumol/g of frozen weight]; in contrast myocardial CP contents decreased significantly [2.71 (+/- 1.44) vs 1.87 (+/- 1.19) mumol/g; p = 0.01]. Following 10 min of reperfusion, the mean ATP level [2.96 (+/- 0.84) mumol/g] was 90% of the preischemic value, and myocardial CP levels (2.32 (+/- 0.92) mumol/g] increased to 85% of preischemic levels. Spontaneous myocardial defibrillation was observed in 93.3% of cases. Early postischemic myocardial function was studied in 228 cardiac operations using the same myocardial protection. 48 patients underwent multiple valve replacement (MUVR), and 180 patients had 4 or more aorto-coronary bypass grafts (CABG). Spontaneous myocardial defibrillation was observed in 90.3% of all; cases; mean CPB time after aortic cross clamp removal was 10.3 (+/- 8) min. Cardiac index by Swan-Ganz thermodilution catheter were measured just before cardiopulmonary bypass and one and twelve hours later.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenosine Triphosphate

[Study of the late results of reimplantation of heart valve prostheses based on 15-year experience].

Authors studied two groups of patients, in which a cardiac valvular prosthesis was reimplanted within 15 years. Data of patients reoperated on (group A) were used to estimate indications, surgical methods, postoperative course and late results. Data of patients which underwent surgery and then requiring reoperation (group B) were used to evaluate the percentage of reoperation falling to 1 patient/1 year according to a primary implanted valvular prosthesis: 42 patients were divided into two groups. 3 perioperative and 12 late deaths (totally 28.3%) were stated in the group A. 5- and 10-year survival rates were 83.3% and 65.6%, respectively. In the group B the lowest percentage of reoperation (1 patient/1 year) were stated in patients with mitral Starr-Edwards 6120 valve (029) and Björk-Shiley aortic valve (0.13). The highest percentage of reoperation was observed in patients with biological prosthetic valves (homograft or heterograft--4.64) and in comparison with patients with primary implanted mechanical prostheses (0.24). Those differences were statistically significant (p less than 0.001).

Adult

[Double mitral and aortic valve replacement: 322 cases operated on between 1970 and 1985].

Over this 15-year period, 322 combined aortic and mitral valve replacements were performed by the same surgeon. Bioprostheses were used in only 4 patients, 318 received a double mechanical prosthesis. The Bjork-Shiley valve was always used for the aortic orifice. For the mitral orifice, three types of valve were implanted: 160 Starr-Edwards 6120 valves, 59 Bjork-Shiley valves and 99 St-Jude Medical valves. The early post-operative mortality was 5.9 p. 100. It was due to cardiac causes in 73.7 p. 100 of the cases and was significantly influenced by the myocardial protection technique (p less than 0.05). A long-term review of the survivors was carried out in november-december, 1986: 15 patients were lost sight of; there were 63 late deaths 77.8 p. 100 of which were either of cardiac origin or due to the prosthesis. 225 patients have survived with a mean follow-up of 79.1 months. The actuarial survival rate (early post-operative mortality included) was 78.2 p. 100 at 5 years and 70.2 p. 100 at 10 years. The incidence of peripheral arterial embolism was 1.9 p. 100 per patient-year, while that of all thromboembolic complications (sudden deaths included) was 3.4 p. 100 per patient-year. The percentages per patient-year of the other complications observed were: haemorrhages 2.2 p. 100, infective endocarditis 0.40 p. 100, reoperation 0.47 p. 100. The proportions of patients free of any complication were 84.8 p. 100 at 5 years and 79.7 p. 100 after 10 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Aortic Valve

[Results of myomectomy in obstructive cardiomyopathy. Apropos of 28 cases].

Hypertrophic obstructive cardiomyopathy, the pathogenesis of which is controverted, exposes the patient to the risk of sudden death and often evolves towards heart failure. When medical treatment is inadequate, surgery may be considered. The authors report their experience of myectomy performed in 28 subjects with pure obstructive cardiomyopathy. Despite a medical treatment based, in most cases, on beta-blockers, all patients showed severe symptoms, with syncopes in 39 p. 100 of the cases, stage 2 or over angina (Canadian Cardiovascular Society grading) in 57 p. 100 of the cases, and stage 3 or over dyspnoea (New York Heart Association grading) in 61 p. 100 of the cases. The intraventricular pressure gradient, measured in 25 patients, was 81.7 +/- 44.9 mmHg. The operation always consisted of myectomy according to the Morrow procedure, i.e. double myotomy of the subaortic septum extended on a length of at least 4 cm, with excision of the muscle between the two incisions. In addition, mitral valve replacement was performed in 13 patients who had severe mitral regurgitation. Three patients (7 p. 100) died with low cardiac output in the peri-operative period; pre-operatively, these patients were in a particularly poor condition. One patient died suddenly during the 4th post-operative month. The annual mortality rate therefore was 2.3 p. 100, and the actuarial survival rate at 8 years was 89.3 p. 100.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult